17. Lingfeng Chen*#, Ruixiang Luo#, Lin Ma#, Ying Xu#, Jiaqi Cao, Zheng Jiang, Shiyan Chen, Xiaohao Huang, Mingwan Zhang, Lei Zheng, Yawen Zhang, Lina Yin, Jie Yu, Xiaochun Zheng, Lulu Zheng, Ping Huang, Guang Liang*. Discovery of LC-MI-3: a potent and orally bioavailable degrader of interleukin-1 receptor-associated kinase 4 for the treatment of inflammatory diseases. Journal of Medicinal Chemistry, 2024, Accepted. (中科院一区，IF=7.3）
16. Binhao Cai#, Ying Xu#, Ruixiang Luo#, Kongqin Lu, Yuhan Wang, Lei Zheng, Yawen Zhang, Lina Yin, Linglan Tu, Wu Luo, Lulu Zheng, Fengzhi Zhang, Xinting Lv, Qidong Tang*, Guang Liang*, Lingfeng Chen*. Discovery of a doublecortin-like kinase 1 inhibitor to prevent inflammatory responses in acute lung injury. Bioorganic Chemistry, 2024, Accepted. (中科院一区，IF=5.1)
15. Lin Ma#, Yingying Li#, Ruixiang Luo#, Yuhan Wang, Jiaqi Cao, Weitao Fu, Bolan Qian, Lei Zheng, Longguang Tang, Xinting Lv, Lulu Zheng*, Guang Liang*, Lingfeng Chen*. Discovery of a selective and orally bioavailable FGFR2 degrader for treating gastric cancer. Journal of Medicinal Chemistry, 2023, 66(11):7438-7453.
14. Lingfeng Chen#, Lili Fu# , Jingchuan Sun#, Zhiqiang Huang#, Mingzhen Fang#, Allen Zinkle, Xin Liu, Junliang Lu, Zixiang Pan, Yang Wang, Guang Liang, Xiaokun Li*, Gaozhi Chen*, Moosa Mohammadi*. Structural Basis for FGF hormone Signaling. Nature, 2023, 618(7966):862-870. (中科院一区Top，IF= 69.50)
13. Ruixiang Luo#, Weitao Fu#, Jingjing Shao#, Lin Ma#, Sujuan Shuai, Ying Xu, Zheng Jiang, Zenghui Ye, Lulu Zheng, Lei Zheng, Jie Yu, Yawen Zhang, Lina Yin, Linglan Tu, Xinting Lv, Jie Li*, Guang Liang*, Lingfeng Chen*. Discovery of a potent and selective allosteric inhibitor targeting the SHP2 tunnel site for RTK-driven cancer treatment. European Journal of Medicinal Chemistry, 2023, 253:115305.
12. Lingfeng Chen#, William M. Marsiglia#, Huaibin Chen#, Joseph Katigbak, Hediye Erdjument-Bromage, David J. Kemble, Lili Fu, Jinghong Ma, Gongqin Sun, Yingkai Zhang, Guang Liang, Thomas A. Neubert, Xiaokun Li, Nathaniel J. Traaseth* & Moosa Mohammadi*. Molecular basis for receptor tyrosine kinase A-loop tyrosine transphosphorylation. Nature Chemical Biology, 2020, 16(3):267-277. (中科院一区Top，IF= 15.04，F1000推荐论文)
11. Lingfeng Chen*, Yanmei Zhang, Lina Yin, Binhao Cai, Ping Huang, Xiaokun Li, Guang Liang*. Fibroblast growth factor receptor fusions in cancer: opportunities and challenges. Journal of Experimental & Clinical Cancer Research, 2021, 40:345. (中科院一区Top，IF= 11.16，通讯作者）
10. Yi Zhang#, Binhao Cai#, Yingying Li#, Ying Xu, Yuhan Wang, Lulu Zheng, Xiaochun Zheng, Lina Yin, Gaozhi Chen, Yunxiang Wang*, Guang Liang*, Lingfeng Chen*. Identification of Linderalactone as a natural inhibitor of SHP2 to ameliorate CCl4-induced liver fibrosis. Frontiers in Pharmacology, 2023, 9;14:1098463. (二区, IF = 5.98，通讯作者)
专著
Fibroblast Growth Factor 23, ELSEVIER, 2021. https://doi.org/10.1016/B978-0-12-818036-5.01001-6. (3/4，Chapter 21)
2020年之前（博士期间）论文发表情况：
9. Lingfeng Chen#，Lulu Zheng#，Pengqin Chen，Guang Liang*. Myeloid Differentiation Primary Response Protein 88 (MyD88): the central hub of TLR/IL-1R signaling. Journal of Medicinal Chemistry, 2020, 63(22):13316-13329. (中科院一区Top, IF= 7.44)
8. Lingfeng Chen#, Hongjin Chen#, Pengqin Chen#, Wenxin Zhang, Chao Wu, Chuchu Sun, Wu Luo, Lulu Zheng, Zhiguo Liu, Guang Liang*. Development of 2-amino-4-phenylthiazole analogues to disrupt myeloid differentiation factor 88 and prevent inflammatory responses in acute lung injury. European Journal of Medicinal Chemistry, 2018, 161:22-38. (中科院一区Top, IF= 6.51)
7. Lingfeng Chen#, Yiyi Jin#, Hongjin Chen#, Chuchu Sun#, Weitao Fu, Lulu Zheng, Min Lu, Pengqin Chen, Gaozhi Chen, Yali Zhang, Zhiguo Liu, Yi Wang, Zengqiang Song*, Guang Liang*. Discovery of caffeic acid phenethyl ester derivatives as novel myeloid differentiation protein 2 inhibitors for treatment of acute lung injury. European Journal of Medicinal Chemistry, 2018, 143: 361-375. (中科院一区Top, IF= 6.51)
6. Lingfeng Chen, Weitao Fu, Lulu Zheng, Yi Wang*, Guang Liang*. Recent Progress in the Discovery of Myeloid Differentiation 2 (MD-2) Modulators for Inflammatory Diseases. Drug Discovery Today, 2018, 23(6):1187-1202. (中科院一区Top，IF= 7.85）
5. Lingfeng Chen, Weitao Fu, Lulu Zheng, Zhiguo Liu, Guang Liang*. Recent progress of small-molecule epidermal growth factor receptor (EGFR) inhibitors against C797S resistance in non-small-cell lung cancer. Journal of Medicinal Chemistry. 2018, 61(10):4290-4300. (中科院一区Top, IF= 7.44)
4. Lingfeng Chen#, Weitao Fu#, Chen Feng#, Rong Qu, Linjiang Tong, Lulu Zheng, Bo Fang, Yinda Qiu, Jie Hu, Peng Zou, Jianpeng Feng, Hua Xie, Jian Ding*, Zhiguo Liu*, Guang Liang*. Structure-based design and synthesis of L858R/T790M selective epidermal growth factor receptor inhibitors for NSCLC. European Journal of Medicinal Chemistry, 2017, 20;140:510-527. (中科院一区Top, IF=6.51)
3. Lingfeng Chen#, Yiyi Jin, Weitao Fu, Chen Feng, Bo Fang, Yugui Gu, Chenglong Li, Yunjie Zhao*, Zhiguo Liu*, Guang Liang*. Design, synthesis and structure-activity relationship analysis of novel thiazolo[3,2-a]pyrimidin derivatives with anti-inflammatory activity in acute lung injury. ChemMedChem, 2017, 12: 1022-1032. (中科院三区，IF= 3.46, 当期封面文章)
2. Zhiguo Liu, #, * Lingfeng Chen#, Pengtian Yu, Yali Zhang, Bo Fang, Chao Wu, Wu Luo, Xianxin Chen, Chenglong Li, Guang Liang*. Discovery of 3-(indol-5-yl)-indazole derivatives as novel myeloid differentiation protein 2/toll-like receptor 4 antagonists for treatment of acute lung injury. Journal of Medicinal Chemistry, 2019, 62(11):5453-5469. (中科院一区Top, IF= 7.44, 当期封面文章)
1. Gaozhi Chen#, Bing Xiao#, Lingfeng Chen#, Bin Bai, Yali Zhang, Zheng Xu, Lili Fu, Zhiguo Liu, Xiaokun Li*, Yunjie Zhao*, Guang Liang*. Discovery of new MD2-targeted anti-inflammatory compounds for the treatment of sepsis and acute lung injury. European Journal of Medicinal Chemistry, 2017, 139: 726-740. (中科院一区Top, IF= 6.51)
